NCI Community Oncology Research Program - Kansas City (NCORP-KC)
NCI Community Oncology Research Program - Kansas City (NCORP-KC)


RTOG-1216:  ORAL CAVITY, OROPHARYNX, LARYNX, or HYPOPHARYNX, Squamous Stg III-IV, M0, post-total resection; RT + concurrent Cisplatin or Docetaxel or Docetaxel & Cetuximab (IMRT credentialing is required – see protocol.)

Effective 2-22-16


ECOG-ACRIN EA6141:  Melanoma, unresectable stage III or stage IV, Nivolumab + Ipilimumab + or - Sargramostim (GM-CSF)

Effective 6-23-17


SWOG S1318:  ALL, new dx, ≥ 65 years old.  Philadelphia negative:  Blinatumomab/POMP.  Philadelphia positive:  Dasatinib/Prednisone/Blinatumomab.  Cohort 2

Effective 9-28-17


Alliance A091401:  Stage IV or unresectable, measurable sarcoma, ≥ 1 prior systemic therapy, nivolumab vs. nivolumab + ipilimumab,

Effective 9-5-18


SWOG S1612:  Untreated AML or MDS with excess blasts,  ≥ 60 years of age, FLT3 testing, Azacitidine vs. Azacitidine + Nivolumab vs. Azacitidine + Midostaurin vs. Decitabine + Cytarabine         

Effective  10-22-18


Alliance A011106:  Neoadj., T2-T4 any N M0, ER+, post-menopausal; Anastrozole vs Fulvestrant vs both ---> Surgery ---> Endocrine therapy x 4.5 yrs (dependent on Modified PEPI score)

Effective 5-9-19







































  © 2013-2019 All Rights Reserved. Privacy Policy | Terms & Conditions
NCI Community Oncology Research Program - Kansas City (NCORP-KC)
Questions? Call: +1-913-948-5588 | Contact Us
4121 W. 83rd St., Suite 259 Prairie Village, KS 66208 USA